Tüdőrák: vizsgálatok itt: Kína
1144 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleFurmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 144
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06674343 - 2. fázisTaking peopleTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 6000
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT04322890 - No phaseNot yet taking people in KínaA Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
- Where
- Shenzhen
- Életkor
- 18 év to 70 év
- People
- 12
- Run by
- BioSyngen Pte Ltd
See details and how to joinNCT06643910 - 3. fázisTaking peopleA Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 632
- Run by
- Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT05487391 - No phaseCsak meghívásosComparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study
- Where
- Xi'an
- Életkor
- 18 év to 75 év
- People
- 660
- Run by
- Xiaolong Yan, Dr.
See details and how to joinNCT06028412 - 1/2. fázisTaking peopleTIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
- Where
- Beijing
- Életkor
- 16 év to 90 év
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT06538012 - 1/2. fázisTaking peopleSafety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Zhou Chengzhi
See details and how to joinNCT06607770 - 2. fázisNot yet taking people in KínaThird-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 30
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT06634667 - 3. fázisTaking peopleSegmentectomy for Solid-dominant Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 277
- Run by
- Fudan University
See details and how to joinNCT06634966 - No phaseTaking peopleAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 1 000 000
- Run by
- Guo ShiWei
See details and how to joinNCT06632886 - No phaseTaking peopleThe Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Ruijin Hospital
See details and how to joinNCT06623487 - Korai 1. fázisNot yet taking people in KínaTP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 9
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT06619886 - 2. fázisNot yet taking people in KínaEfficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 296
- Run by
- Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT06620822 - 3. fázisTaking peopleEfficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 180
- Run by
- Zhou Chengzhi
See details and how to joinNCT06607796 - 2. fázisTaking peopleALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 90
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT05014464 - 2. fázisTaking peopleSunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 100
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT06355609 - 2. fázisTaking peopleInduction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 100
- Run by
- Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT05766800 - No phaseTaking peopleImproving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma
- Where
- Wuhan
- Életkor
- 20 év to 80 év
- People
- 3000
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT05830812 - 2. fázisTaking peoplePhase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
- Where
- Huizhou, Lianyungang, Nanyang, Tianjin, Weihai
- Életkor
- 18 év to 75 év
- People
- 148
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06141226 - 2. fázisTaking peopleSunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 52
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT06348927 - 1/2. fázisTaking peopleHypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
- Where
- Hefei
- Életkor
- 18 év to 70 év
- People
- 45
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT06527898 - 1. fázisNot yet taking people in KínaA Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 350
- Run by
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT06594874 - 2. fázisNot yet taking people in KínaBronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction
- Where
- Changsha
- Életkor
- 18 év to 80 év
- People
- 39
- Run by
- Hunan Province Tumor Hospital
See details and how to joinNCT06604351 - 1. fázisNot yet taking people in KínaClinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT06585059 - 2. fázisNot yet taking people in KínaA Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 44
- Run by
- Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT06585644